PSILONEX

PSILONEX is a proprietary **psilocybin-based pharmaceutical program** being developed by Allied for mental health disorders including **depression, anxiety, and post-traumatic stress disorder**. Based on the provided context, the program is structured as a two-phase regimen consisting of **PSILONEX Rx**, a pharmaceutical psilocybin formulation intended for the acute treatment phase, followed by **PSILONEX Daily**, a cannabinoid maintenance therapy. The core active psychedelic ingredient identified for the PSILONEX drug concept is **psilocybin**, a small-molecule serotonergic psychedelic whose therapeutic effects are generally attributed primarily to agonism of **serotonin 2A receptors** and related serotonergic signaling. The available information indicates that Allied advanced PSILONEX Rx into **Phase 1** development by November 2021.

Other names

psilocybin-based formulation